CAS 1163719-56-9

Cct196969

CAS: 1163719-56-9

Formula: C₂₇H₂₄FN₇O₃

Purity: 98%

Molecular weight: 513.5230

Ref: IN-DA0096DJ

CCT196969

CAS: 1163719-56-9

CCT196969

Purity: ≥98%

Molecular weight: 513.52g/mol

Ref: 54-BUP10019

CCT196969

CAS: 1163719-56-9

CCT196969 is a novel orally available, pan-RAF inhibitor with anti-SRC activity. It also inhibits SRC, LCK, and the p38 MAPKs.

Formula: C₂₇H₂₄FN₇O₃

Purity: 98.93% - 99.65%

Color and Shape: Solid

Molecular weight: 513.52

Ref: TM-T4133

Cct196969

CAS: 1163719-56-9

Cct196969

Molecular weight: 513.52g/mol

Ref: 54-BISN0303

CCT196969

Controlled Product

CAS: 1163719-56-9

Formula: C₂₇H₂₄FN₇O₃

Color and Shape: Neat

Molecular weight: 513.523

Ref: TR-C227940

Cct196969

CAS: 1163719-56-9

CCT196969 is a drug candidate that has been shown to have anti-cancer properties. It has been shown to inhibit the growth of xenograft tumours in mice and may be effective against solid tumours. CCT196969 is thought to work by interfering with the apoptosis pathway, which leads to cancer cell death. This drug candidate inhibits the production of nuclear DNA, which may be an indication of its ability to target cancer cells. CCT196969 also has a biochemical effect on other genes that are related to cancer, such as epidermal growth factor (EGF) and basic fibroblast growth factor (bFGF). This drug candidate could potentially be used as a treatment for skin cancers or other types of cancer in the future.

Formula: C₂₇H₂₄FN₇O₃

Purity: Min. 95%

Molecular weight: 513.52 g/mol

Ref: 3D-NWB71956